NCT00171899

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will assess the role of high-dose imatinib mesylate, in patients who have taken imatinib mesylate for at least 1 year at the standard dose, in achieving a major molecular response (a measure of the level of chronic myelogenous leukemia) versus the standard dose.

Conditions

• Chronic Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	imatinib mesylate

Timeline

• Start date: 2005-04-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2005-09-15
• Last updated: 2017-02-23

Locations

1 site across 1 country: Canada